Current bioactivity findings for newly launched and developmental drugs, including calculated properties based on chemical structures and searchable 3D models.
MDDR contains over 150,000 biologically relevant compounds and well-defined derivatives. Updates add about 10,000 substances a year to the database. MDDR covers patent literature, journals, meetings, and congresses.
Formerly MDL Drug Data Report, MDDR is produced by Symyx and Prous Science (part of the scientific business of Thomson Reuters).
Medicinal chemists, pharmacologists, and molecular modelers use the database to create SAR tables (matching chemical structure to pharmacological effect) and find competitive information about compounds similar to their lead compounds.
MDDR provides:
- Chemical structure
- Calculated properties based on chemical structure
- 3D models (calculated with Corina)
- Compound name – trademarks and company codes
- CAS registry number
- Biological activity based on the Prous classification system
- Description of therapeutic action
- Containing ED50, LD50, inhibition values, etc.
- Patent information including patent number, title, source, priority number and inventor’s names
- Literature references
- Hyperlinked to primary literature (full text, abstracts, patents, conference proceedings, etc.)
- Company codes, generic names, trade names and trademark names
- Originating company
- Development phase in the R&D process